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Abstract 
Context: Exercise for prostate cancer survivors could be beneficial. However, no systematic review 
across cancer stages and treatment types addressing potential benefits and harms exists to date. 
Objectives: Primarily, to assess the effects of exercise on cancer specific quality of life and adverse 
events in prostate cancer trials. 
Evidence acquisition: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, 
EMBASE, AMED, CINAHL, PsycINFO, SPORTDiscus and PEDro. We also searched grey literature 
databases, including trials registers. Searches were from database inception to March 2015. 
Standardised mean differences (SMD) were calculated for meta-analysis. 
Evidence synthesis: We included 16 RCTs involving 1574 men with prostate cancer. Follow-up varied 
from just eight weeks to 12months. RCTs involved men with stages I-IV cancers. High risk of bias was 
frequently due to attrition and intervention adherence. Seven trials involving 912 men measured 
cancer specific quality of life. No significant effect on this outcome was found from pooling the data 
from these seven trials (SMD = 0.13, 95% CI = -0.08, 0.34, median follow-up 12 weeks). Sensitivity 
analysis of studies that were judged to be of high quality indicated a moderate positive effect 
estimate (SMD = 0.33, 95% CI = 0.08, 0.58, median follow-up 12 weeks). Similar beneficial effects 
were seen in cancer specific fatigue, submaximal fitness and lower body strength. We found no 
evidence of benefit for disease progression, cardiovascular health or sexual function. There were no 
deaths attributable to exercise interventions. Other serious adverse events (e.g. myocardial 
infarction) were equivalent to those seen in controls.  
Conclusions: These results support exercise interventions for improving cancer specific quality of life, 
cancer specific fatigue, submaximal fitness and lower body strength.  
Patient summary: This review shows that exercise or physical activity interventions can improve 
quality of life, fatigue, fitness and function for men with prostate cancer.  
 
 
1. Background  
Prostate cancer is the primary cause of years lived with cancer disability in the Americas, North-
western European, Australia and New Zealand and much of sub-Saharan Africa.[1]  Management of 
prostate cancer, ranges from no intervention (active surveillance or watchful waiting) to radical local 
treatment (prostatectomy and radiation therapy) with or without combined androgen deprivation 
therapy (ADT), ADT alone, to taxane-based chemotherapy for progressive castration-resistant 
disease [2] and second line hormone agents. [3, 4]  First-line radical treatment for prostate cancer 
can negatively impact quality of life (e.g. erectile dysfunction, incontinence, radiation proctitis), as 
can ADT (e.g. loss of muscle mass, fatigue, psychological morbidity, increased cardiovascular and 
bone fracture risk). [5, 6] Direct symptoms from advanced or metastatic cancer (e.g. pain, 
hypercalcaemia, spinal cord compression, pathological fractures) can also adversely affect health. [7, 
8] 
 
Several recent systematic reviews have examined the effects of exercise in cancer survivors, in terms 
of quality of life outcome [9, 10], exercise behaviour [11] and effects on fatigue. [12] These reviews 
are an amalgamation of heterogeneous primary cancers. Indeed, most evidence comes from trials in 
breast cancer and as such cannot be generalised to men with prostate cancer. Further, exercise 
therapy appears beneficial in the short term, but little is known about dose, duration and longer-
term effects of such therapy, including adverse effects over an extended follow-up. Finally, despite 
the potential health benefits for men with prostate cancer, few clinicians are aware of the role of 
exercise, and in many cases it goes un-prescribed. The aim of this review was primarily to evaluate 
the effect of exercise interventions on cancer specific quality of life after prostate cancer diagnosis 
and assess adverse effects.    
 
 
 
2. Evidence acquisition  
Methods for this systematic review have been described in detail elsewhere.[13] Briefly, the primary 
review outcomes were quality of life and adverse events. Secondary outcomes include the effect on 
fatigue, disease progression, cardiovascular health, physical fitness/function and sexual function.  
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, 
AMED, CINAHL, PsycINFO, SPORTDiscus and PEDro databases from inception to March 31st 2015. We 
expanded the database search by attempting to identify unpublished studies and references in the 
grey literature (i.e. via the OpenGrey database). We also searched the WHO trials page and the 
ISRCTN meta-Register of Controlled Trials and ClinicalTrials.gov.  
 
2.1 Inclusion / exclusion criteria 
We included only randomised controlled trials (RCTs) involving adults. Participants in these trials 
must have been diagnosed with prostate cancer. Only interventions that included a component 
targeted at increasing aerobic exercise and/or resistance exercise behaviour compared with a usual 
care or ’waiting list’ control group with at least six weeks of follow-up (from trial baseline 
assessment) were included in this review. We excluded trials that address recovery of continence 
only. Investigators must have reported frequency, duration and intensity of aerobic exercise 
behaviour, or frequency, intensity, type, sets and repetitions of resistance exercise behaviour as 
prescribed in the intervention.   
 
2.2 Data extraction 
After extraction piloting, three review authors worked independently (LB,  DS and AC) to screen all 
titles and abstracts identifying records that met the inclusion criteria, or that could not be safely 
excluded without assessment of the full text (e.g. when no abstract was available). Disagreements at 
this stage were resolved by discussion with another review author (DJR). Full-text articles for these 
records were retrieved. After training to ensure a consistent approach to study assessment and data 
abstraction, three review authors worked independently (LB, DS and AC) to assess the retrieved full-
text articles. We documented the selection process in a PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) study flow diagram.[14] 
 
Review authors did not conduct data extraction from any primary studies for which they have been 
listed as an author. Data were entered into the statistical software of The Cochrane Collaboration, 
Review Manager (RevMan 5) for calculation of meta-analyses. We contacted study authors to 
request information that was missing from reports of included studies (where appropriate). 
Risks of bias was assessed using The Cochrane Collaboration tool. [15] Two of three review authors 
(LB, DS and AC) applied the risk of bias tool independently to each study. Differences were resolved 
by discussion or by appeal to a third review author (DJR). Review authors who were authors of 
included studies did not perform risk of bias assessment for studies that they had authored. We 
summarised results in a risk of bias summary figure.  
 
2.3 Data synthesis 
If data were sufficient and if it was appropriate to do so, we performed a meta-analysis. Meta- 
analysis was performed by LB using Review Manager software. RH performed I2 calculations in 
STATA. If statistical heterogeneity was noted, meta-analysis were  performed using a random-effects 
model. Fixed-effect models were used only if no significant statistical heterogeneity were present. 
We noted the time points at which outcomes were collected and reported. If adverse effects data 
were insufficient, or if meta-analysis were determined not to be appropriate, we provided a 
narrative synthesis. 
 
For continuous outcomes (e.g. cancer-specific quality of life), we extracted the point estimate for the 
measure of central tendency for the final value of the outcome of interest and the number of 
participants assessed at stated follow-up in each treatment arm to estimate the standardised mean 
difference (SMD) between treatment arms and its 95% confidence interval (CI).  
 
2.4 Unit of analysis issues 
We did not include cross-over trials in this review because of the difficulty involved in ‘washing out’ 
behaviour change interventions. For trials with multiple intervention groups, we first eliminated 
groups for which the intervention did not meet the criteria for inclusion in the review; we then 
combined all relevant intervention groups to create a single pair-wise comparison with the control 
group.  
 
2.5 Assessment of heterogeneity 
We used clinical expertise to judge whether it was appropriate to combine trials in a meta-analysis. 
Consistency of results was assessed using the I2 statistic and, its 95% confidence limits. Data were 
analysed using RevMan and Stata 12 (RevMan; Stata). 
 
2.6 Sensitivity analysis 
Results of meta-analyses were interpreted in light of the findings with respect to risk of bias. Risk of 
bias is assessed for each follow-up, and for the sensitivity analysis we used the longest follow-up for 
which there is low risk of bias. We contacted study authors for additional information or for further 
clarification of study methods if any doubt arose regarding sources of bias (where appropriate). 
 
2.7 Sub-group analysis 
If a sufficient number of studies were identified, and if resolution of reporting is adequate, we 
performed subgroup analyses. These were: anticancer treatment received, cancer stage, obesity , 
previously physically active participants at baseline, explanatory (efficacy) versus pragmatic 
(effectiveness) trial designs. We categorised interventions according to theoretical basis; behaviour 
change techniques and categorisation using the Coventry, Aberdeen & London-Refined (CALO-RE) 
taxonomy.[14]  
 
3. Results  
3.1 Results of the search 
Figure 1 illustrates the results of the literature searches and screening process for the review. We 
identified 4356 unique records from database searches and 22 manuscripts through grey literature 
and hand checking of references from included studies and related systematic reviews[16, 17]. After 
reviewing by title and abstract we further evaluated 91 records by full text, after which, 67 studies 
were excluded from the review. All full text manuscripts were available in English. We sent 31 emails 
requesting further information to published manuscripts, we received 4 responses (only one of 
which provided new data). 
 
3.2 Included studies  
We included 16 RCTs (please see Table 1 for descriptions) [18-33] including 1574 men with prostate 
cancer (sample size range 423 to 20). We also found eight linked secondary analysis manuscripts.[34-
41] All studies were randomised at the patient level. Follow-up varied from just eight weeks to 12 
months. RCTs involved men with stages I-IV cancers but no trials were found in men exclusively 
undergoing chemotherapy (two trials included a small proportion of men who had chemotherapy) 
[26, 33]. Exercise interventions were either supervised [22, 27, 29-31], home-based [21, 24, 32], a 
mix of supervised and home-based [18, 23, 25, 33], supervised with suggested home-based activity 
[19, 20] and two were unclear.[26, 28] Exercise behaviour (dose) was monitored using objective [22, 
29-32], subjective [24, 26], a mixture of objective or subjective methods[18, 23, 25, 33], was not 
monitored [21] or was unclear. [19, 20, 27, 28] All trials included a usual care comparator. Two trials 
supplemented usual care with standard exercise advice for cancer survivors.[23, 26] As our previous 
Cochrane review[11] has demonstrated that simple advice is highly unlikely to improve exercise 
behaviour, we judged these studies were eligible for inclusion.  
 
The behaviour change techniques used primarily focused on instruction on how to perform 
behaviour with practice and goals set by trainers. Three trials[18, 21, 26] reported a more 
psychological approach to changing behaviours by incorporating techniques such as problem solving, 
social support and client set goals. Of interest in comparison to our previous review, significantly 
more studies reported that they taught generalisation of behaviour, however, association with 
outcome was not possible in this review due to small numbers of studies per outcome. All studies 
were conducted in countries categorised as ’high income’ by the WHO. 
 
3.3 Risk of bias and quality of included studies 
Figure 2 illustrates risk of bias judgements made for included studies. Online supplement 1 describes 
the detail of risk of bias judgements.  All trials were judged to have a high risk of bias for blinding of 
participants given that it is not possible to blind the participant in an exercise intervention. We did 
not, however, judge that this necessarily compromised study quality. The most common issues 
around high risk of bias that would impact on study quality were level of study attrition during at 
least one follow-up point, poor intervention adherence, lack of investigator blinding and selective 
reporting bias. 
 
3.4 Effects of interventions on primary review objectives 
Seven trials involving 912 men measured cancer specific quality of life using a tool that gave an 
overall/summary score that could be entered into a meta-analysis. [18, 22, 25-27, 29, 30] No 
significant effect on this outcome was found from pooling the data from these seven trials (SMD = 
0.13, 95% CI = -0.08, 0.34). No statistical heterogeneity was observed (I2 = 46%, 95% CI = 0 to 76). 
Sensitivity analysis of studies that were judged to be of high quality[18, 22, 30] (NB Bourke 2014 
three month follow-up data was used) indicated a moderate positive effect estimate (SMD = 0.33, 
95% CI = 0.08, 0.58) with no significant heterogeneity (I2 = 0%, 95% CI = 0, 73). Please see Figure 3 for 
forest plot.  
 
Ten studies reported information on adverse events involving 685 men. Four studies reported no 
adverse events. [20, 22, 28, 33] Two studies reported deaths, one due to lung cancer [23] and one in 
the control arm of the trial.[18] One incidence of acute MI (no previous cardiac history) was 
reported requiring hospitalisation and resuscitation after only the third day of the aerobic training 
protocol.[30] In the Galvão 2014 trial, one participant in the control group with no previous history 
of cardiac disease had a nonfatal myocardial infarction during the second half of the study but had a 
full recovery. One study reported three incidences of adverse ECG changes during exercise testing, 
reflected by significant ST segment depression in 3 patients. [25] One study reported two incidences 
of fractures of the fibula in the intervention group [31] with one of the occurrences revealing 
underlying peripheral neuropathy. One study described an incident where one man in the exercise 
group fell while dressing at home and suffered a fractured rib [19] but was able to complete the final 
2 weeks of the intervention with a modified prescription. Three studies reported mixed musculo-
skeletal complications from pre-existing back and knee pain [23], training-induced leg cramps or 
back pain [25] and three incidences of minor tendon/ligament/quadriceps injury [31] with exercise. 
 
3.5 Secondary review outcomes 
Positive beneficial effects were seen on cancer specific fatigue, lower body strength and aerobic 
fitness. Please see online supplement 2 for details of secondary review outcomes meta-analysis. No 
effect was seen on cardiovascular health or disease progression outcomes. A borderline positive 
effect was seen on sexual activity (P=0.05) but no effect on sexual function. 
 
 
3.6 Planned sub-group analysis and CALO-RE behaviour change technique taxonomy. 
Please see online supplement 3 for planned sub-group outcomes and the results of the CALO-RE 
taxonomy data. 
 
4. Discussion 
Sixteen trials involving 1574 men with prostate cancer were included in the review. From sensitivity 
analysis, we found high quality evidence that exercise interventions can improve cancer specific 
quality of life and cancer specific fatigue in men with prostate cancer at up to six months of follow-
up (with moderate beneficial effect estimate). There were no deaths attributable to exercise 
interventions. Other serious adverse events as a result of exercise (e.g. MI) were equivalent to those 
seen in controls. In one trial which used a competitive, contact sport as the intervention (football) a 
high rate of lower limb fracture was seen in the intervention arm. More frequently, soft tissue 
complications such as minor musculo-skeletal sprains and strains were reported from intervention 
groups in more controlled settings. No effect was seen on cardiovascular health or disease 
progression outcomes. Positive beneficial effects were seen on lower body strength alongside 
positive effects on aerobic fitness. A borderline positive effect was seen on sexual activity, but this 
should be viewed with caution as these data are taken from two small trials. 
 
We specifically only selected trials for this review which report key metrics of exercise prescription in 
order to support reproducibility. In doing so we have synthesised 11 more RCTs than a recent 
systematic review. [17] Further, to the authors knowledge, this is the first review to have been able 
to report quantified meta-analysis of effect estimates around key patient related outcomes such as 
cancer specific quality of life and fatigue. Our review offers the most up to date evidence on adverse 
effects systematically gathered from an exhaustive review of RCTs. Our meta-analysis of 
improvements in sexual activity is unique but should be interpreted with caution as data are taken 
from just two available trials.  
Much of the uncertainty in judging trial bias came from poor reporting around randomisation 
procedures, both sequence generation and allocation concealment: however no trials were judged 
to be at high risk of bias. As with other systematic reviews our group has undertaken in exercise and 
cancer populations [11], we have not penalised trials for being at high risk of performance bias for 
blinding of participants. Further, bias is not likely as trials with poor adherence to the exercise 
intervention, commonly produce no effect on clinical outcomes.[24, 26] It is not possible to blind 
participants to taking part in an exercise intervention. Some trials have suggested this should be 
addressed by “sham” exercise conditions. However, given that aerobic exercise recommendation 
guidelines for survivors are not only freely available on the web (e.g. from the American Cancer 
Society) but are also often positively promoted by care providers and cancer support charities 
(e.g.Macmillan), the legitimacy of any “sham” condition seems dubious.  
 
Like any behaviour change intervention, requiring participants to maintain exercise behaviour can be 
very challenging and lead to issues with retention and adequate ’dose’ of the intervention, actually 
being received. The majority of the reasons trials were judged to have a high risk of bias was due to 
attrition and adherence biases, which we judged would have a substantial impact on the quality of 
evidence. Selective reporting biases - particularly with regards to adverse events -  was the other 
most prevalent issue. 
 
Three studies reported data on up to 12months of follow-up [23, 25, 33], however all were judged to 
be at high risk of bias. As such to harmonise where possible with other high quality evidence, we 
only extracted six month data for use in meta-analyses. As such, long term durability of some of the 
key findings of this review, are uncertain. The studies reported here are very often a mixture of T 
stage cancers, with some studies e.g. [29, 30] including T 1-4 men. This limits the certainty to which 
we are able to make recommendations, stratified by disease stage (indeed we were not able to 
conduct planned sub-group analysis). This is also true in regards to treatment type, although, several 
meta-analyses of high quality studies are largely representative of men on ADT. High quality studies 
of men with earlier stages of disease undergoing radical treatment are required. No evidence was 
found for men undergoing chemotherapy (apart from a very small minority of the cohort in two 
trials)[26, 33] and further, it is not clear what value exercise interventions have in men on newer 
hormone treatments e.g. Enzalutamide.  Also, we did not find any evidence of men undergoing more 
recent radical innovations such as HIFU. 
 
All studies were taken from peer reviewed journals as we were unable to locate any unpublished 
results, despite contacting internationally recognised experts in the field. We found some evidence 
that exercise might have a beneficial impact on sexual activity, but in the absence of concurrent 
improvements in sexual function, the value of this finding to patients is uncertain. It should also be 
noted that the majority of these interventions took place in a controlled environment. 
All studies were conducted in countries classified as high income by the WHO taxonomy. No 
evidence was derived from developing countries, and it is uncertain whether the resources and/or 
infrastructure required for some of the interventions included in this review would be available in 
these other parts of the world. Very few trials reported baseline ethnicity data, but what was 
available seems to indicate the large majority of studies involve Caucasian men. Given prostate 
cancer disproportionally effects other ethnic groups e.g. black men, it should be noted that these 
men are underrepresented in these trials. We were not able to identify any trials that satisfied our 
pragmatic design criteria, and as such these data should be considered to address efficacy of these 
interventions rather than effectiveness in health services. Our review objective to assess the effect 
of exercise interventions on disease progression was difficult to achieve.  We were only able to 
undertake a synthesis of PSA data measured as a secondary outcome in underpowered trials. This 
finding should be viewed with much caution. Trials that evaluate the impact of exercise on 
dichotomous outcomes such as progression-free survival or overall mortality would be an excellent 
addition to the field. 
The mechanisms whereby exercise interventions improve cancer specific quality of life remain 
speculative. It was beyond the scope of this review to undertake any formal analysis of mechanisms. 
Improvements in fatigue, lower limb function and exercise capacity are potentially occurring due to 
well established adaptations associated with exercise training, such as improvements in cardiac 
output, metabolic adaptations, skeletal muscle motor unit recruitment etc. Exercise has also been 
linked to improving negative physiological changes associated with advanced cancer such as 
cachexia. [42] To what extent this contributes to improved physical functioning and QoL is uncertain.  
A substantive psychological benefit related to empowerment and self-efficacy could be a factor. 
Formal mediator and moderator studies would be useful to address this uncertainty. A number of 
studies included dietary interventions as part of a lifestyle intervention. Although not formally 
analysed, most studies reported minimal impact on dietary outcomes, thus suggesting the 
predominant effector in the intervention was the exercise component. 
 
The key recommendations from this review are that treating clinicians and guidelines bodies should 
be cognisant that there is level 1 evidence that exercise interventions are efficacious for improving 
cancer specific quality of life, fatigue, and exercise capacity in men with prostate cancer. Much of 
the high quality evidence comes from trials involving men on ADT. There is very early evidence 
(which should be interpreted with caution, owing to limited number of trials) that exercise could also 
be useful for improving sexual activity. Trials are ongoing to look at these outcomes.[43] Any 
exercise programme should be individually tailored and work with the individuals physical 
capabilities and limitations.[11] The treating clinician should play a role in directly advocating the 
benefits of exercise to men with prostate cancer and leading the multidisciplinary team in the 
referral process. Where possible, men should be sign-posted to relevant exercise referral schemes 
e.g. in the community. Ideally, behavioural change support should also be offered to maximise 
adherence and also include periodic re-evaluation of exercise prescription, either in terms of 
tapering or progression. Effectiveness and cost-effectiveness data for these interventions when 
integrated into health care services would be informative. 
  
5. Conclusions 
There is level 1 evidence that exercise interventions are efficacious for improving cancer specific 
quality of life, fatigue, and exercise capacity in men with prostate cancer. The high quality evidence 
comes mainly from men on ADT with advanced disease. Adverse events such as minor soft tissue 
injuries (sprains and strains) can be expected in a minority of men but can also be mitigated by 
properly tailored exercise prescription and progression around individual capabilities / existing co-
morbidities. We found no evidence that exercise improved cardiovascular health but we were 
limited to synthesising evidence around blood pressure only. Effectiveness and cost-effectiveness 
data for these interventions when integrated into health care services would be informative. 
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Figure 2: Risk of bias graph for included trials. 
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Figure 2: Assessment of risk of bias from included RCTs.  
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ONLINE SUPPLEMENT 1: RISK OF BIAS JUDGEMENTS 
Allocation 
Random sequence generation 
Ten studies reported enough information for a judgement of low risk regarding randomisation 
sequence generation (Bourke 2014; Cormie 2013; Cormie 2015; Galvão 2010; Galvão 2014 
McGowan 2013; Park 2012; Segal 2003; Segal 2009; Windsor 2004). In all other trials, insufficient 
information was present to permit judgement. 
 
Allocation concealment 
Nine studies reported enough information for a judgement of low risk allocation concealment 
(Bourke 2014; Cormie 2013; Cormie 2015; Dieperink 2013; Galvão 2010; Jones 2014, Segal 2003; 
Segal 2009; Windsor 2004). In all other trials, insufficient information was present to permit 
judgement. 
 
Blinding 
Blinding of participants and personnel 
All studies were judged to have a high risk of performance bias, as it would not be possible to blind 
participants or personnel in an exercise intervention.  
 
Blinding of outcome assessment 
We assessed risk of bias for blinding of outcome assessment on an outcome specific basis, i.e. 
objective vs. subjective outcomes.  
 
Objective outcomes (cardiovascular health and disease progression) 
Eight studies reported objective outcome data. Only three studies used any form of blinding for 
assessment of objective outcomes. Bourke 2014 and Jones 2014 used blinded trials staff to assess 
blood pressure, whilst Hebert 2012 sent PSA to external laboratories. Five other studies collecting 
objective outcomes (Cormie 2015; Galvão 2010; Galvão 2014; Segal 2003; Segal 2009) reported 
insufficient information to permit a judgment on bias. 
 
Subjective outcomes (cancer specific quality of life, cancer specific fatigue, physical function, sexual 
function) 
Fifteen trials reported subjective outcomes data. Five studies reported blinding techniques for 
subjective outcomes. Jones 2014 and Segal 2003 reported blinding for all trial subjective 
assessments. Bourke 2014 and Dieperink 2013 ensured that questionnaires (assessing quality of life, 
atigue and sexual function) were completed independently by participants. Windsor 2004 also 
ensured that questionnaires were completed independently by participants but blinding for shuttle 
tests in not clear. Bourke 2014 used blinding for assessment of physical function test (i.e. 
submaximal fitness). Winters-stone 2014 reported that tests were administered by trained 
technicians blinded to group assignment. Seven trials were judged to have an unclear risk of bias due 
to insufficient reporting (Cormie 2013; Cormie 2015; Galvão 2010; McGowan 2013; Monga 2007; 
Park 2012; Segal 2009). Two trials were judged to have a high risk of bias, as they reported using 
unblinded assessors for physical function tests (Galvão 2014; Uth 2014). Hebert 2012 did not report 
any subjective outcomes.  
 
Incomplete outcome data 
We assessed risk of bias for incomplete outcome data on an outcome specific basis, i.e. objective vs. 
subjective outcomes. 
 
Objective outcomes (cardiovascular health and disease progression) 
Of the eight studies reporting objective outcome data, six were judged to have a low risk of attrition 
bias (<20%), five reporting PSA (Cormie 2015; Galvão 2010;Hebert 2012; Segal 2003; Segal 2009) and 
two reporting blood pressure data (Cormie 2015; Jones 2014). Two studies were judged to have high 
risk of attrition bias. For blood pressure data, Bourke 2014 reported 32% study attrition at six 
months of follow-up (three months after the end of the intervention) and Galvão 2014 reported 22% 
study attrition at 12months of follow-up for blood pressure and PSA data. 
 
Subjective outcomes (cancer specific quality of life, cancer specific fatigue, 
physical function, sexual function) 
Five studies reported low attrition bias (<20%) for quality of life (Dieperink 2013; Galvão 2010; Jones 
2014; Segal 2003; Segal 2009). Three trials reported high attrition bias for quality of life at one study 
assessment point. McGowan 2013 and Monga 2007 reported 28 and 30% study attrition 
(respectively) at the single study follow-up point, whereas Bourke 2014 reported 32% attrition at six 
months of follow-up only (three months after the end of the intervention). 
 
Seven studies reported low attrition bias for fatigue (Cormie 2015; Galvão 2010; Jones 2014; Segal 
2003; Segal 2009; Windsor 2004; Winters-Stone 2014). Four trials reported high attrition bias for 
fatigue. Cormie 2013;McGowan 2013 and Monga 2007 reported 25, 28 and 30% study attrition 
(respectively) at the single study follow-up point, whereas Bourke 2014 reported 32% attrition at six 
months of follow-up only (three months after the end of the intervention). 
 
Seven studies reported low attrition bias for physical function tests (Cormie 2015; Galvão 2010; 
Jones 2014; Segal 2003; Segal 2009; Uth 2014; Winters-Stone 2014). Five trials reported high 
attrition bias for physical function data. Cormie 2013; Monga 2007; Park 2012 reported 25, 30 and 
23% study attrition (respectively) at the post-intervention follow-up point. Bourke 2014 reported 
32%attrition at six months of follow-up only (three months after the end of the intervention). Galvão 
2014 reported only 57 data points from 100 men randomised for the study dynamic strength tests. 
 
Three studies reported low attrition bias for sexual function outcomes (Dieperink 2013; Galvão 2010; 
Jones 2014). Cormie 2015 was judged to have a high risk of bias as only 17 data points were 
reported from 63 men randomised for sexual function for domain of the QLQ-PR25 questionnaire. 
 
Ten studies reported conforming to intention-to-treat analysis  (Cormie 2013; Cormie 2015; 
Dieperink 2013; Galvão 2010; Galvão 2014; Hebert 2012; Jones 2014; Segal 2003; Segal 2009; 
Winters-Stone 2014). Five trials were unclear in their reporting of this analysis method (McGowan 
2013; Monga 2007; Park 2012;Uth 2014;Windsor 2004). Bourke 2014 analysed data from men 
according the groups to which were randomised, but did not impute data. Further, a sensitivity 
analysis of outcomes was performed to ensure confidence of results. 
 
Selective reporting 
Nine trials reported all specified outcomes of interest in the review (Bourke 2014; Cormie 2013; 
Cormie 2015; Galvão 2010; Galvão 2014; Jones 2014; Segal 2009; Uth 2014; Winters-Stone 2014). 
Ten studies reported adverse events (Bourke 2014; Cormie 2013; Cormie 2015; Galvão 2010; Galvão 
2014; Jones 2014; Park 2012; Segal 2009; Uth 2014; Winters-Stone 2014). We judged the six trials 
which failed to report adverse events or reported them incompletely (Dieperink 2013; Hebert 2012; 
McGowan 2013; Monga 2007; Segal 2003; Windsor 2004) as having a high risk of bias, given that this 
information should be reported as standard in any interventional clinical trial. Further, three trials 
(Park 2012; Segal 2003; Windsor 2004) reported outcomes incompletely (physical function, PSA and 
fatigue, respectively) preventing them from being entered into a meta-analysis. 
 
Other potential sources of bias 
Three trials were judged to have low risk of other biases (Bourke 2014; Segal 2003; Uth 2014). Six 
trials were judged to have a high risk of other biases. Galvão 2014; and Windsor 2004 reported that 
there was no significant difference in exercise behaviour between intervention and control groups 
over the study follow-up points. Also, Hebert 2012 reported exercise behaviour at six months which 
was lower than at baseline in the intervention arm. Jones 2014 reported a substantial contamination 
in the control arm at six months of follow-up. Low adherence to the intervention was reported in the 
McGowan 2013 (13.6%) and Winters-Stone 2014 (43% adherence to the home-only component). 
Winters-Stone 2014 failed to recruit target trial sample. 
 
Other sources of bias were judged to be unclear in seven studies. Exercise adherence data was 
missing for the suggested home-based component of the prescription in Cormie 2013; Cormie 2015 
and Galvão 2010. No exercise adherence data was reported from the Dieperink 2013; Monga 2007 
and Park 2012 trials. Segal 2009 did not report assumptions for the imputation of missing data. 
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ONLINE SUPPLEMENT 2: REVIEW SECONDARY OUTCOMES 
 
Cancer specific fatigue (up to six months follow-up) 
Ten trials involving 1031 men measured cancer specific (Bourke 2014; Cormie 2013A; Cormie 2015; 
Galvão 2010; Jones 2014; McGowan 2013; Monga 2007; Segal 2003; Segal 2009; Winters-Stone 
2014). Data from Cormie 2013A; Galvão 2010; Monga 2007 and Winters-Stone 2014 was reversed 
(multiplied by -1) to allow for combination with other outcomes tools with directional differences. 
Windsor 2004 measured fatigue but did not report data in a format that was possible to enter into a 
meta-analysis. A mild positive effect on this outcome was found from combining these studies 
(SMD= 0.25, 95%CI = 0.02, 0.49) with substantial heterogeneity (I2 = 61, 95% CI =0, 79). Sensitivity 
analysis of studies that were judged to be of high quality (Bourke 2014; Cormie 2015; Galvão 2010; 
Segal 2009: NB Bourke 2014 three month follow-up data was used) indicated a moderate positive 
effect estimate (SMD = 0.45, 95% CI = 0.22, 0.67) with no significant heterogeneity (I2 = 37%, 95% CI 
= 0, 78). 
 
 
Disease progression (up to six months follow-up) 
Five trials involving 388 men measured PSA (Cormie 2015; Galvão 2010; Galvão 2014; Hebert 2012; 
Segal 2003: NB Galvão 2014 six month follow-up data was used). Segal 2003 reported PSA data 
incompletely so that it cannot be entered in a meta-analysis. No significant effect on PSA was found 
(SMD = 0.14, 95% CI = -0.06, 0.35) with no significant heterogeneity (I2 = 0, 95% CI = 0, 64).  
 
 
Cardiovascular health (up to six months follow-up) 
Systolic blood pressure 
Four trials involving 298 men measured systolic blood pressure (Bourke 2014; Cormie 2015;Galvão 
2014; Jones 2014:NB Galvão 2014 six month and Bourke 2014 three month follow-up data was used). 
No significant effect on systolic blood pressure was found (SMD = -0.10, 95% CI = 0.33, 0.13) and no 
statistical heterogeneity (I2 = 47%, 95% CI = 0, 81). This finding was supported (SMD = -0.13, 95% CI = 
-0.45, 0.19) by including only high quality studies (Bourke 2014; Cormie 2015).  
 
 
 
 
 
 
Diastolic blood pressure (up to six months follow-up) 
Four trials involving 298 men measured systolic blood pressure (Bourke 2014; Cormie 2015; Galvão 
2014; Jones 2014: NB Galvão 2014 six month and Bourke 2014 three month follow-up data was 
used). No significant effect on systolic blood pressure was found (SMD = -0.18, 95% CI = -0.41, 0.04) 
and no statistical heterogeneity (I2 = 45%, 95% CI = 0, 80).This finding was supported (SMD = -0.11, 
95% CI = -0.44, 0.21) by including only high quality studies (Bourke 2014; Cormie 2015).  
 
 
 
Physical fitness/function (up to six months follow-up) 
VO2 peak 
Three trials involving 220 men measured VO2 peak (Jones 2014; Segal 2009; Uth 2014). A borderline 
significant positive effect was observed for this outcome (SMD = 0.27, 95% CI = 0.00, 0.54) with no 
significant heterogeneity (I2 = 0%, 95% CI = 0, 73). No sensitivity analysis of high quality trials was 
possible as only one of these three studies is judged to be of high quality (Segal 2009). 
 
Sub-maximal aerobic fitness 
Six studies involving 346 men measured sub-maximal fitness (Bourke 2014; Cormie 2013A; Cormie 
2015; Galvão 2010; Galvão 2014; Monga 2007: NB Galvão 2014 six month and Bourke 2014 three 
month follow-up data was used). Data from Cormie 2013A; Cormie 2015; Galvão 2010; Galvão 2014 
was reversed (multiplied by -1) to allow for directional differences with outcome assessment 
methods. A significant positive effect estimate was observed for this outcome (SMD = 0.49, 95% CI = 
0.12, 0.85) with no significant heterogeneity (I2 = 61%, 95% CI =0, 82). Sensitivity analysis of studies 
that were judged to be of high quality (Bourke 2014; Cormie 2015; Galvão 2010 NB Bourke 2014 
three month follow-up data was used) indicated a moderate positive effect estimate (SMD = 0.40, 
95% CI = 0.12, 0.68) with no significant heterogeneity (I2 = 67%, 95% CI = 0, 88). 
Park 2012 and Segal 2003 reported data that was of insufficient clarity to allow it to be entered into 
this meta-analysis. However, these studies were judged to be at high risk of bias and as such would 
not alter the sensitivity analysis results. 
 
 
 
Upper body strength 
Four studies involving 277 men assessed upper body strength (Cormie 2015; Galvão 2010; Segal 
2009 and Winters-Stone 2014). A significant improvement in upper body strength was observed 
(SMD = 0.26, 95% CI = 0.02, 0.51) with no significant heterogeneity (I2 = 0%, 95% CI =0, 68). 
Sensitivity analysis of high quality trials indicates no effect (SMD = 0.23, 95% CI = -0.03, 0.49) with no 
significant heterogeneity (I2 = 0%, 95% CI =0, 73). 
 
  
 
 
 
Lower body strength 
Six studies involving 245 men assessed lower body strength (Cormie 2013A; Cormie 2015; Galvão 
2010; Segal 2009; Uth 2014; Winters-Stone 2014). A significant positive effect estimate was 
observed for this outcome (SMD = 0.29, 95% CI = 0.07, 0.50) with no significant heterogeneity (I2 = 
0%, 95% CI =0, 75). Sensitivity analysis of studies that were judged to be of high quality (Cormie 2015; 
Galvão 2010; Segal 2009) confirmed this (SMD = 0.34, 95% CI = 0.07, 0.60) with no significant 
heterogeneity (I2 = 0, 95% CI = 0, 73).  
  
 
 
Sexual function  
Function (up to six months follow-up) 
Three studies involving 212 men assessed sexual function (Cormie 2015; Dieperink 2013; Jones 
2014). No significant effect on sexual function was observed (SMD = 0.21, 95% CI = -0.06, 0.49) with 
no significant heterogeneity (I2 = 47%, 95% CI = 0, 84). Sensitivity analysis was not possible as two 
out of these three trials are judged as having a high risk of bias. 
 
 
Sexual activity (up to three months follow-up) 
Two trials involving 119 men assessed sexual activity (Cormie 2015; Galvão 2010). A borderline 
positive effect estimate was observed (SMD = 0.37, 95% CI = 0.00, 0.73) with no significant 
heterogeneity (I2 = 57%, P = 0.13. NB 95% CI are not calculable with only 1 degree of freedom). 
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ONLINE SUPPLEMENT 3 
Planned subgroup analysis 
Our planned subgroup analysis was not possible due to the following reasons: 
 
• Anti-cancer treatment received: trials involved a mixture of different anti-cancer 
treatments in their study sample, or studies of high quality were all conducted in men 
on the same treatment e.g. see Analysis 1.2 where in the three high quality studies, 
all men were on ADT in Bourke 2014; Galvão 2010 and the majority of men were on 
ADT (61%) in Segal 2009. 
 
• Cancer stage: studies rarely reported full TNM data for their cohorts. Where T 
stage data was available, this always involved multiple T stages making specific 
comparisons not possible. 
 
• Obese cohorts: where BMI data was available, no obese cohorts were reported. 
 
• Previously physically active participants at baseline: in the majority of studies, 
reporting of baseline physical activity was either not reported or was reported as a 
proportion of the cohort at baseline that was sedentary vs those that were active. 
Further, definitions of what constitutes previously physically active was also variable 
(e.g. currently meeting physical activity guidelines of 150 minutes per week [Cormie 
2015] or not moderately active for more than 90 minutes per week [Bourke 2014]). In 
four trials that could be interpreted as having participants not regularly active at 
baseline, two trials were judged as having a high risk of bias (Galvão 2014; Jones 
2014) and one did not report any review outcomes of interest (Winters-Stone 2014). 
 
• Explanatory (efficacy) versus pragmatic (effectiveness) trial designs: we had 
planned to designate studies as pragmatic if they met the following criteria: an 
exclusively non physically active cohort at baseline, a clinically meaningful primary 
outcome, a multi-centre study, usual care comparators, no restrictions on exercise 
behaviour in comparator, a co-morbidity profile representative of the prostate cancer 
population being tested and use of intent-to-treat analysis. This was based on 
previously published criteria for pragmatic trials (Thorpe 2009). No studies met these 
criteria. 
 
 
 
 
 
 
 
 
 
 
  
 
CALO-RE taxonomy analysis 
AE – Aerobic Exercise, RE – Resistance Exercise, UC- Usual care, NR – None reported 
BCT 
Segal (2009) Segal 
(2003) 
Cormie 
(2013a) 
Cormie 
(2015) 
Dieperink 
(2013) 
Galvao 
(2010) 
 
AE RE UC 
(NR) 
RE C  AE/
RE 
UC AE/
RE 
UC I UC AE/
RE 
UC 
1. Provide info on 
consequences in general 
             
2. Provide info on 
consequences of 
behaviour to the 
individuals 
             
3. Provide information 
about others approval 
             
4. Provide normative 
information about others 
behaviour 
             
5. Goal Setting 
(behaviour) - with client 
         X    
5b. Goal Setting 
(behaviour) - by PT 
X X  X  X  X  X  X  
6. Goal Setting (outcome)              
7. Action Planning X X  X  X  X  X  X  
8. Barrier 
identification/problem 
solving 
         X    
9. Set graded tasks X X  X  X  X    X  
10. Prompt review of 
behavioural goals 
         X    
11. Prompt review of 
outcome goals 
             
12. Prompt rewards 
contingent on effort or 
progress towards 
behaviour 
             
13. Provide rewards 
contingent on successful 
behaviour 
             
14. Shaping              
15. Prompting 
generalisation of a target 
behaviour 
     X  X  X   ?  
16. Prompt self-
monitoring of behaviour  
             
17. Prompt self-
monitoring of behavioural 
outcome 
             
18. Prompting focus on 
past success 
             
19. Provide feedback on 
performance 
             
20. Provide information 
on where and when to 
perform the behaviour 
X X  X    X  X    
21. Provide instruction on 
how to perform the 
behaviour 
X X  X  X  X  X  X  
22. Model/Demonstrate 
the behaviour 
             
23. Teach to use 
prompts/cues 
             
24. Environmental 
restructuring 
             
25. Agree behavioural 
contract 
             
26. Prompt practice X X  X  X  X  X  X  
27. Use of follow-up 
prompts  
             
28. Facilitate social 
comparison 
             
29. Plan social 
support/social change 
         X    
30. Prompt identification 
as role model/position 
advocate 
             
31. Prompt anticipated 
regret 
             
32. Fear arousal              
33. Prompt self-talk              
34. Prompt use of imagery              
35. Relapse 
prevention/coping 
planning 
             
36. Stress 
management/emotional 
control training 
             
37. Motivational 
interviewing 
         X    
38. Time-management              
39. General 
communication skills 
training 
             
Stimulate anticipation of              
future rewards 
 
AE – Aerobic Exercise, RE – Resistance Exercise, UC- Usual care, NR – None reported, PII – Personal 
implementation intention, TII- telephone Implementation intention, FB – Football, SE- Stretching 
Exercise 
BCT 
Galvao 
2014 
Jones 2014 McGowan 
2013 
Monga 
2007 
Park 2012 Uth 2014 Wint
Stone  
 
 
 
RE 
& 
AE  
C - AE UC - PII TII AE UC AE & 
RE 
UC FB UC RE   
 
 
 
1. Provide info on 
consequences in general 
      X X           
2. Provide info on 
consequences of 
behaviour to the 
individuals 
                  
3. Provide information 
about others approval 
                  
4. Provide normative 
information about others 
behaviour 
                  
5. Goal Setting 
(behaviour) - with client 
      X X           
5b. Goal Setting 
(behaviour) - by PT 
X X  X   X X X  X  X  X    
6. Goal Setting (outcome)                   
7. Action Planning X   X   X X X  X  X  X    
8. Barrier 
identification/problem 
solving 
      X X           
9. Set graded tasks X   X         X  X    
10. Prompt review of 
behavioural goals 
                  
11. Prompt review of 
outcome goals 
                  
12. Prompt rewards 
contingent on effort or 
progress towards 
behaviour 
                  
13. Provide rewards 
contingent on successful 
behaviour 
                  
14. Shaping                   
15. Prompting 
generalisation of a target 
behaviour 
X   X           X    
16. Prompt self-
monitoring of behaviour  
X                  
17. Prompt self-
monitoring of behavioural 
outcome 
X        X          
18. Prompting focus on 
past success 
                  
19. Provide feedback on 
performance 
X                  
20. Provide information 
on where and when to 
perform the behaviour 
X        X    X      
21. Provide instruction on 
how to perform the 
behaviour 
X   X   X X X  X  X  X    
22. Model/Demonstrate 
the behaviour 
                  
23. Teach to use 
prompts/cues 
      X X           
24. Environmental 
restructuring 
                  
25. Agree behavioural 
contract 
                  
26. Prompt practice X   X     X  X    X    
27. Use of follow-up 
prompts  
X                  
28. Facilitate social 
comparison 
                  
29. Plan social 
support/social change 
                  
30. Prompt identification 
as role model/position 
advocate 
                  
31. Prompt anticipated 
regret 
                  
32. Fear arousal                   
33. Prompt self-talk                   
34. Prompt use of imagery                   
35. Relapse 
prevention/coping 
planning 
                  
36. Stress 
management/emotional 
control training 
                  
37. Motivational 
interviewing 
                  
38. Time-management                   
39. General 
communication skills 
training 
                  
Stimulate anticipation of 
future rewards 
                  
 
AE – Aerobic Exercise, RE – Resistance Exercise, UC- Usual care, NR – None reported, PII – Personal 
implementation intention, TII- telephone Implementation intention, FB – Football, SE- Stretching 
Exercise 
BCT 
Windsor 
2004 
Hebert 2012 
 AE UC - AE   
1. Provide info on 
consequences in general 
      
2. Provide info on 
consequences of 
behaviour to the 
individuals 
      
3. Provide information 
about others approval 
      
4. Provide normative 
information about others 
behaviour 
      
5. Goal Setting 
(behaviour) - with client 
      
5b. Goal Setting 
(behaviour) - by PT 
X   X   
6. Goal Setting (outcome)       
7. Action Planning X   X   
8. Barrier 
identification/problem 
solving 
      
9. Set graded tasks    X   
10. Prompt review of 
behavioural goals 
      
11. Prompt review of 
outcome goals 
      
12. Prompt rewards 
contingent on effort or 
progress towards 
behaviour 
      
13. Provide rewards 
contingent on successful 
behaviour 
      
14. Shaping       
15. Prompting 
generalisation of a target 
behaviour 
   X   
16. Prompt self-
monitoring of behaviour  
X      
17. Prompt self-
monitoring of behavioural 
outcome 
X      
18. Prompting focus on 
past success 
      
19. Provide feedback on 
performance 
      
20. Provide information 
on where and when to 
perform the behaviour 
      
21. Provide instruction on 
how to perform the 
behaviour 
X   X   
22. Model/Demonstrate 
the behaviour 
      
23. Teach to use 
prompts/cues 
      
24. Environmental 
restructuring 
      
25. Agree behavioural 
contract 
      
26. Prompt practice X   X   
27. Use of follow-up 
prompts  
   X   
28. Facilitate social 
comparison 
      
29. Plan social 
support/social change 
X   X   
30. Prompt identification 
as role model/position 
advocate 
      
31. Prompt anticipated 
regret 
      
32. Fear arousal       
33. Prompt self-talk       
34. Prompt use of imagery       
35. Relapse 
prevention/coping 
planning 
      
36. Stress 
management/emotional 
control training 
   X   
37. Motivational 
interviewing 
      
38. Time-management       
39. General 
communication skills 
training 
      
Stimulate anticipation of 
future rewards 
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Study 
author 
N randomised Follow-up Participants & Treatment Intervention 
 
Review outcome measures 
Bourke 
2014 
Exercise n= 50, 
Usual care n= 50 
Baseline, three 
and six months. 
• Tumour stage(s): T3,T4 
• Current cancer 
treatment: ADT 
• Metastatic disease: 11 
men in the intervention 
group vs 9 in the control 
group 
-Aerobic frequency: three times per week 
-Aerobic intensity: 55-75% of age predicted maximum 
heart rate or 11-13 on the Borg 
Rating of Perceived Exertion scale 
-Aerobic duration: 30 minutes 
-Resistance frequency: three times per week 
-Resistance sets: between two and four 
-Resistance reps: eight-12 repetitions 
-Resistance load: 60% of one repetition max 
• Cancer specific quality of life: FACT-P 
questionnaire 
• Adverse events: reported 
• Cancer specific fatigue: FACT-F questionnaire 
• Cardiovascular health: systolic and diastolic 
blood pressure. 
• Physical function: aerobic exercise tolerance 
by sub-maximal treadmill test. 
 
Cormie 
2013A 
Exercise n=10, 
Usual care n=10 
Baseline and 12 
weeks 
• Tumour stage(s): not 
clear 
• Current cancer 
treatment: unclear. All 
men had previous ADT 
• Metastatic disease: all 
men had metastatic 
disease 
-Aerobic frequency: unclear 
-Aerobic intensity: unclear 
-Aerobic duration: 150 mins of total exercise per week 
-Resistance frequency: twice weekly 
-Resistance sets: two to four sets per exercise 
-Resistance reps: 12-8 repetitions 
-Resistance load: 12-8 repetition maximum (RM) 
• Adverse events: reported 
• Cancer specific fatigue: the Multidimensional 
Fatigue Symptom Inventory-Short Form 
questionnaire 
• Physical function: (1) one repetition max in 
leg extension (2) 400-m walk, (3) usual and fast 
pace 6-m walk, (4) timed 'up and go' test 
Cormie 
2015 
Exercise n= 32, 
Usual care n= 31 
baseline, three 
months 
• Tumour stage(s): not 
clear 
• Current cancer 
treatment: ADT, 
radiation 
• Metastatic disease: 
none 
-Aerobic frequency: twice weekly 
-Aerobic intensity: target intensity was set at 
approximately 70-85% of estimated maximum heart 
rate.  
-Aerobic duration: 20-30 minutes supervised  
-Resistance frequency: twice weekly 
-Resistance sets: 1-4 sets per exercise 
-Resistance reps: 6-12 repetition maximum 
-Resistance load: 60-85% of one repetition maximum 
• Cancer specific quality of life: QLQ-PR25 
questionnaire 
• Adverse events: reported 
• Cancer specific fatigue: FACT-F questionnaire 
• Disease progression: PSA 
• Cardiovascular health: Systolic and diastolic 
blood pressure 
• Physical function: 400 m walk (s), leg press 
(kg), chest press (kg), seated row (kg) 
• Sexual function: sexual function domain on 
QLQ-PR25 questionnaire 
 
Dieperink 
2013 
Intervention n=79, 
control n= 
82 
12 weeks before 
radiotherapy, pre-
intervention (4 
weeks 
after 
• Tumour stage(s): T1-T3 
• Current cancer 
treatment: radiotherapy 
and ADT 
• metastatic disease: 
-Aerobic frequency: seven days per week 
-Aerobic intensity: bottom limit for moderate-
intensity physical exercise corresponds to walking at 
an average speed of 4 km/h (taken from the 
recommendations from the National Board of Health 
• Cancer specific quality of life: EPIC 
questionnaire 
• Sexual function: EPIC questionnaire sexual 
sum score 
 
radiotherapy), 21-
22 weeks from 
pre-intervention 
three patients in each 
randomisation group 
received pelvic 
radiotherapy due to 
metastatic lymph nodes 
in Denmark) 
-Aerobic duration:30 minutes per day 
 
 
 
 
 
 
 
 
Galvão 
2010 
Exercise n= 29, 
usual care n= 28 
Baseline, 12 
weeks 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: radiation & 
ADT 
• Nodal metastases: 
exercise = 2 , UC = 3 
-Aerobic frequency: twice per week.  
-Aerobic Intensity: 65% to 80% maximum heart rate 
and perceived exertion at 11 to 13 (6 to 20 point, Borg 
scale) 
-Aerobic duration: 15 to 20 minutes of cardiovascular 
exercises. * 
-Resistance frequency: twice per week. 
-Resistance sets: two to four sets 
-Resistance reps: 12 to 6 
-Resistance load: 12 to 6 repetition maximum 
 
*Participants encouraged to supplement with exercise 
at home to reach 150 mins/week 
• Cancer specific quality of life: assessed using 
QLQ-C30 and QLQ PR 25 questionnaires 
• Adverse events: reported 
• Cancer specific fatigue: assessed with fatigue 
domain of the QLQ-C30 questionnaire 
• Disease progression: PSA 
• Physical function: 400m walk, upper and 
lower body dynamic strength 
• Sexual function: sexual activity assessed using 
the QLQ PR 25 questionnaire 
 
Galvão 
2014 
Exercise n= 50, 
Usual care n= 50 
Baseline, six and 
12 months 
• Tumour stage(s): T2, 
T3,T4 
• Current cancer 
treatment: None. 
Previous ADT & radiation 
& bisphosphonate 
• Metastatic disease: 
excluded from trial 
-Aerobic frequency: 4 times per week 
-Aerobic intensity: 70-85% maximum heart rate and 
perceived exertion at 11-13 (6- to 
20-point Borg scale) 
-Aerobic duration: 20-30 min of cardiovascular 
exercises 
-Resistance frequency: twice per week  
-Resistance sets: two to four sets 
-Resistance reps: 12 to 6 
-Resistance load: 12 to 6 repetition maximum 
• Adverse events: reported 
• Disease progression: PSA 
• Cardiovascular health: blood pressure 
• Physical function: sub-maximal exercise 
tolerance, chair rise test 
Hebert 
2012 
Exercise n=29, 
Control n=25 
Baseline, three 
and six months 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: previously 
treated with surgery, 
radiotherapy or both 
• Metastatic disease: 
-Aerobic frequency: five times per week 
-Aerobic intensity: (3.0-6.0 METs or 4-7 kcal/min) 
(taken from cited ACSM guidelines on what 
constitutes moderate intensity exercise) 
-Aerobic duration: ≥30 minutes 
• Adverse events: unclear 
• Disease progression: PSA 
 
unclear 
Jones 2014 Exercise n= 25, 
Usual care n= 25 
Baseline and six 
months. 
• Tumour stage(s): T I, T 
II 
• Current cancer 
treatment: Previous 
bilateral nerve-sparing 
RP 
• Metastatic disease: 
none 
-Aerobic frequency: five sessions per week 
-Aerobic intensity: 55% to 100% of VO2 peak 
-Aerobic duration: 30 to 45 mins per session 
 
• Cancer specific quality of life: assessed by 
FACT-G and FACT-P questionnaires 
• Adverse events: reported 
• Cancer specific fatigue: assessed by FACT-F 
questionnaire 
• Cardiovascular health: blood pressure 
• Physical function:VO2peak 
• Sexual function: International Index of 
Erectile Function  questionnaire 
 
 
 
McGowan 
2013 
Physical activity 
guidelines n= 141. 
Self-administered 
implementation 
intention n = 141. 
Telephone assisted 
implementation 
intention n =141. 
 
Baseline one and 
three months. 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: watchful 
waiting, surgery, 
radiotherapy, ADT, 
chemotherapy, ’cancer 
recurrence’ 
• Metastatic disease: 
1.9% of the cohort had 
metastatic disease. 
-Aerobic frequency: unclear 
-Aerobic intensity: *Taken from citation 22* 
approximately equivalent to 500 to 1,000 metabolic 
equivalent (MET) minutes a week 
-Aerobic duration: 150minutes to 300minutes (5 
hours) per week, or to increase physical activity by at 
least 60 min/week if they were already meeting the 
guidelines 
• Cancer specific quality of life: assessed using 
the FACT-P questionnaire sub-scale 
• Cancer specific fatigue: assessed using the 
FACT-F questionnaire 
 
Monga 
2007 
Unclear (30 men 
randomised in 
total) 
Baseline and eight 
weeks 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: radiotherapy 
• Metastatic disease: 
unclear 
-Aerobic frequency: three times per week 
-Aerobic intensity: the following formula was used to 
calculate target heart rate: (.65) (maximum heart rate 
resting heart rate) resting heart rate 
-Aerobic duration: 30-minute aerobic segment 
consisting of walking on a treadmill 
• Cancer specific quality of life: FACT-P 
questionnaire 
• Cancer specific fatigue: assessed using the 
Piper fatigue scale 
• Physical function: submaximal fitness (Bruce 
treadmill protocol) and timed five repetition 
chair sit-to-stand test. 
 
Park 2012 Exercise n= 33, 
Usual care n= 33 
The week before 
surgery, before 
exercise (3 weeks 
postoperatively), 
• Tumour stage(s): pT2a 
- pT3a 
• Current cancer 
treatment: post radical 
-Aerobic frequency: twice per week 
-Aerobic intensity: 45%-75%of the heart rate reserve 
maximum and 9-13 rated perceived exertion 
-Aerobic duration: 60 minutes 
• Adverse events: reported 
• Physical function: sit-ups, chair stand, 
dominant grip strength, adduction ability, 
back lift, and knee lift were performed for 2 
and after exercise 
(15 weeks 
postoperatively).    
 
prostatectomy 
• Metastatic disease: 
unclear 
minutes 
 
 
 
 
 
Segal 2003 Exercise n= 82, 
Control n=73 
Baseline and 12 
weeks 
• Tumour stage(s): T 
stage I-IV 
• Current cancer 
treatment: ADT 
• Metastatic disease: 
unclear 
-Resistance frequency: three times per week 
-Resistance sets: two 
-Resistance reps: eight to 12 
-Resistance load: 60% to 70% of one-repetition 
maximum 
• Cancer specific quality of life: FACT-P 
questionnaire 
• Cancer specific fatigue: FACT-F questionnaire 
• Disease progression: PSA 
• Physical function: dynamic upper and lower 
body muscle endurance 
Segal 2009 Resistance exercise 
n= 40, Aerobic 
exercise n= 40, 
control n= 41 
Baseline, 12 
weeks, 24 weeks 
• Tumour stage(s): stage 
I-IV 
• Current cancer 
treatment: radiation and 
ADT (61% of cohort on 
ADT) 
• Metastatic disease: 
none (excluded from 
trial) 
-Aerobic frequency: three times per week 
-Aerobic intensity: up to 60% of predetermined peak 
oxygen consumption (VO2peak) 
for weeks 1 to 4 and progressing to 70% to 75% for 
weeks 5 to 24 
-Aerobic duration: exercise duration began at 15 
minutes and increased by 5 minutes every 3 weeks 
until it reached 45 minutes 
-Resistance frequency: three times per week 
-Resistance sets: two 
-Resistance reps: eight to 12 
-Resistance load: 60% to 70% of estimated one-
repetition maximum (1 RM) 
• Cancer specific quality of life: assessed by 
FACT-P questionnaire 
• Adverse events: reported 
• Cancer specific fatigue: assessed by FACT-F 
questionnaire 
• Disease progression: assessed by PSA 
• Physical function: VO2 peak, upper and lower 
body dynamic strength 
Uth 2014 Exercise n= 29, 
Usual care n= 28 
Baseline and 12 
weeks 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: ADT 
(previous radiotherapy / 
radiation) 
• metastatic disease: 
nodal metastases, 
exercise = 14%, usual 
care = 35%. Bone 
metastases, exercise = 
-Aerobic frequency: two to three times per week 
-Aerobic Intensity: 70-100% HRmax 
-Aerobic duration: during the first 4 weeks, the 
football training consisted of two weekly sessions, 
which started with 15 min of warm-up exercises 
(running, dribbling, passing, 
shooting, balance, and muscle strength exercises) 
followed by 2 × 15 min of 5-7 a-side small-sided 
games. In weeks 
5-8, the duration of each session increased to 3 × 15-
min games after the warm-up, and in weeks 9-12, 
• Adverse events: reported 
• Physical function: VO2peak, knee-extensor 
maximal strength, chair sit-to-stand test 
24%, usual care = 15% there were three weekly training sessions of the same 
duration 
Windsor 
2004 
Exercise n=33, 
Control n= 33 
Baseline, four and 
eight weeks 
• Tumour stage(s): 51 of 
65 patients had tumours 
that were classified as T1 
or T2. 
• Current cancer 
treatment: All 
Radiotherapy and 19 of 
66 patients (28.8%) were 
receiving adjuvant 
hormone therapy for 
high-risk tumours, 
including 10 of 33 
patients 
in the control group and 
9 of 33 patients in the 
exercise group 
• Metastatic disease: 
unclear 
-Aerobic frequency: at least 3 days of each week of 
radiotherapy 
-Aerobic intensity: 60-70% of calculated maximum 
heart rate 
-Aerobic duration: 30 minutes 
• Cancer specific fatigue: assessed using the 
Brief Fatigue Inventory questionnaire 
Winters-
Stone 
2014 
Exercise n=29, 
Control n= 22 
Baseline, six and 
12 months 
• Tumour stage(s): 
unclear 
• Current cancer 
treatment: all men on 
ADT. 45 and 50% of men 
received 
radiotherapy (exercise vs 
control, respectively) 
and 7 and 14% of men 
received 
chemotherapy (exercise 
vs control, respectively). 
• Metastatic disease: 
exercise = 27.6%, control 
= 13.6% 
-Resistance frequency: three times per week 
-Resistance sets: displacement 1 to 10, lower body 1 
to 2, upper body 1 to 2 
-Resistance reps: displacement 10, lower body 8 to 12, 
upper body 14 to 8 
-Resistance load: lower body and displacement 0 to 
15% of body weight. Upper body, 15 to 10 repetition 
max 
• Adverse events: reported 
• Cancer specific fatigue: Schwartz Cancer 
Fatigue Scale 
• Physical function: Bench press 1RM (kg), Leg 
press 1RM (kg), Chair stand (s), 4-m fast walk 
(m/s) 
 
 
Key. FACT-P = Functional assessment of cancer therapy - prostate. FACT-G = Functional assessment of cancer therapy - general. FACT-F = Functional assessment of cancer 
therapy- fatigue. QLQ-C30 European Organisation for Research and Treatment of Cancer core quality of life questionnaire. QLQ-PR25 = European Organisation for Research 
and Treatment of Cancer Prostate-specific module (QLQ-PR25). EPIC = Expanded Prostate Cancer Index Composite. RM = Repetition maximum. HR = Heart rate.  
          
          
          
          
  
 
 
 
 
 
